Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Stifel Maintains Buy on Globus Medical, Raises Price Target to $70

Author: Benzinga Newsdesk | May 08, 2024 09:21am
Stifel analyst Mathew Blackman maintains Globus Medical (NYSE:GMED) with a Buy and raises the price target from $64 to $70.

Posted In: GMED